Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals, the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan A. J. W.
  • Ferrari, Matteo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • McNamara, Iain R.
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Waiyan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia|||0000-0001-8138-0874
  • Ustianowski, Andrew P.
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Del-Toro-López, Maria Dolores
The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres. This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables. The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI. This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections, a post-hoc analysis of a multicentre prospective cohort in Spain

  • Gómez-Zorrilla, S.
  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Sendra, Elena|||0000-0002-4374-2173
  • Zamorano, L.
  • Grau, I.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, E.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • López Montesinos, I.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Cotarelo, M.|||0000-0002-7017-0369
  • Cantón, R.
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, P.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48-72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11-4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37-25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25-4.69), cephalosporins (2.14; 1.35-3.41), and imipenem or meropenem (2.08; 1.03-4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain, Findings from the Multicenter ITUBRAS-2 Cohort Study

  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Hernández García, Marta
  • Xanthopoulou, K.|||0000-0001-8591-8184
  • Gijón, Desiré
  • Siverio Pares, Ana Cristina
  • Berbel, Dàmaris|||0000-0002-3689-3360
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Rivera, Alba|||0000-0002-9709-6162
  • de Malet, A.
  • Xercavins, M.|||0000-0003-1463-6344
  • Ruiz De Gopegui, E.
  • Canoura-Fernández, L.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Seral, C.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Cotarelo, M.|||0000-0002-7017-0369
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Higgins, P.G.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, A.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Ruiz-Garbajosa, P.
  • Montesinos, I.L.
  • Merino, I.
  • de Gopegui, E.R.
  • López-Causapé, C.
  • Grau, I.
  • Sabé, N.
  • Shaw, E.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Sendra, E.
  • Rubio, V.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Badía, C.
  • Calvo, E.
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Morte-Romea, E.
  • Paño-Pardo, J.R.
  • Carmona-Torre, F.
  • Quintano, F.T.
  • Sánchez Carrillo, Carlos
  • Cortarelo, M.
Background: The objective of this study was to assess the microbiological and clinical features of Klebsiella pneumoniae health care-associated bacteremia of urinary origin (HCA-BUO) in Spain, with a focus on third-generation cephalosporin-(3GCR-Kp) and carbapenem-resistant K pneumoniae (CR-Kp) isolates. Methods: A total of 96 (21.4%, 96/449) K pneumoniae blood isolates were prospectively collected from patients with HCA-BUO (n = 443) from 12 tertiary care hospitals in Spain (2017-2019). Antimicrobial susceptibility was determined (standard broth microdilution), and extended-spectrum β-lactamase, AmpC, and carbapenemase production was screened. A subset of 55 K pneumoniae isolates was analyzed by whole genome sequencing (Illumina) to determine population structure, resistome, and virulome. Additionally, 13 of these isolates were subjected to long-read sequencing (Nanopore) for plasmid characterization. Patients' baseline and clinical characteristics were reviewed. Results: 3GCR-Kp prevalence was 43.8% (42/96), mostly associated with extended-spectrum β-lactamase production (34/96, 35.4%; mainly CTX-M-15, 32/34, 94.1%) and the dissemination of sequence type (ST)-307 (15/34, 44.1%) and other globally spread multidrug-resistant high-risk clones. CR-Kp prevalence was 9.4% (9/96); all isolates belonged to different STs and were mostly associated with carbapenemase production (6/9, 66.7%; mainly OXA-48-like, n = 3). Additionally, 3GCR-Kp and CR-Kp isolates showed higher content of other antibiotic resistance genes. Altogether, these episodes were associated with prior antibiotic use and receipt of inadequate empirical treatment. Conclusions: There is a high prevalence of 3GCR and CR-Kp causing HCA-BUO in Spain, mainly driven by the dissemination of ST307/CTX-M-15 and other globally spread multidrug-resistant high-risk clones, challenging the selection of empirical and targeted treatments for these infections.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infection in European hospitals: the COMBACTE-NET ARTHR-IS multi-centre study

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad
  • Mur, Isabel
  • Tedeschi, Sara
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa
  • Murillo, Óscar
  • Soldevila-Boixader, Laura
  • Scarborough, Mathew
  • Scarborough, Claire
  • Kluytmans, Jan
  • Ferrari, Matteo Carlo
  • Pletz, Mathias W.
  • Mcnamara, Iain
  • Escudero-Sánchez, Rosa
  • Arvieux, Cédric
  • Batailler, Cecile
  • Dauchy, Frédéric-Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena-Segovia, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele
  • Bagnoli, Fabio
  • Rodríguez-Baño, Jesús
  • Toro, María Dolores del
© 2023 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background] The aim of this study was to estimate the incidence, associated disease burden and healthcare utilization due to Staphylococcus aureus prosthetic joint infections (SA-PJI) after primary hip and knee arthroplasty in European centres., [Methods] This study was conducted in patients who underwent primary hip and knee arthroplasty in 19 European hospitals between 2014 and 2016. The global incidence of PJI and SA-PJI was calculated. The associated disease burden was measured indirectly as infection-related mortality plus loss of function. For healthcare utilization, number and duration of hospitalizations, number and type of surgical procedures, duration of antibiotic treatments, and number of outpatient visits were collected. Subgroup and regression analyses were used to evaluate the impact of SA-PJI on healthcare utilization, controlling for confounding variables., [Results] The incidence of PJI caused by any micro-organism was 1.41%, and 0.40% for SA-PJI. Among SA-PJI, 20.7% were due to MRSA with substantial regional differences, and were more frequent in partial hip arthroplasty (PHA). Related deaths and loss of function occurred in 7.0% and 10.2% of SA-PJI cases, respectively, and were higher in patients with PHA. Compared with patients without PJI, patients with SA-PJI had a mean of 1.4 more readmissions, 25.1 more days of hospitalization, underwent 1.8 more surgical procedures, and had 5.4 more outpatient visits, controlling for confounding variables. Healthcare utilization was higher in patients who failed surgical treatment of SA-PJI., [Conclusions] This study confirmed that the SA-PJI burden is high, especially in PHA, and provided a solid basis for planning interventions to prevent SA-PJI., This work was supported by the Innovative Medicines Initiative Joint Undertaking (grant agreement No. 115523), COMBACTE-NET consortium (European Union FP7/2007–2013 and GlaxoSmithKline Biologicals SA, as EFPIA partner). R.E., L.S, O.M., R.E.-S., J.L.-T., J.P., J.R.-B. and M.D.del T. are members of the Spanish Network for Research in Infectious Diseases (REIPI), supported by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0005; 0009; 0011; 0015), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligence Growth 2014–2020. M.W.P. was partly supported by the German Research Foundation (GRK 2723, project number 444711651)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla, Belén
  • Benito, Natividad
  • Boix-Palop, Lucía
  • Fariñas, Maria Carmen
  • Peñaranda, María
  • Gamallo, Maria Rocío
  • Martinez, Jose Antonio
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis
  • Durán-Jordá, Xavier
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael
  • Oliver, Antonio
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo
  • Siverio, Ana
  • Gijón, Desiré
  • Merino, Irene
  • López-Causapé, Carla
  • Sabé, Nuria
  • Shaw, Evelyn
  • Berbel, Dámaris
  • Tubau Quintano, Fe
  • Sánchez Carrillo, Carlos
  • Cercenado, Emilia
  • Sendra, Elena
  • Rubio, Verónica
  • Rivera, Alba
  • Calvo, Esther
  • Badía, Cristina
  • Xercavins, Mariona
  • de Malet, Ana
  • Canoura-Fernández, Luis
  • Salvo, Soledad
  • Paño-Pardo, Jose Ramón
  • Carmona-Torre, Francisco
Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77–6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27–6.44) and Charlson index (aOR 1.11; 95% CI 1.01–1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40–0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. © 2021, The Author(s).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multi drug resistance in healthcare-associated bacteremic urinary tract infections: a post-hoc analysis of a multi center prospective cohort in Spain

  • Gómez Zorrilla, S.
  • Becerra Aparicio, F.
  • Sendra, E.
  • Zamorano, L.
  • Grau, I.
  • Pintado, V.
  • Padilla, B.
  • Benito, N.
  • Boix Palop, L
  • Fariñas, M.C.
  • Peñaranda, M.
  • Gamallo, M.R.
  • Martínez, J.A.
  • Morte Romea, E.
  • Del Pozo, J.L.
  • López Montesinos, I.
  • Durán Jordá, X.
  • Ponz, R.
  • Cotarelo, M.
  • Cantón, R.
  • Oliver, A.
  • Ruiz Garbajosa, P.
  • Horcajada, J.P.
Background: The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48–72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11–4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37–25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25–4.69), cephalosporins (2.14; 1.35–3.41), and imipenem or meropenem (2.08; 1.03–4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publicación

Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections, what is the Influence of XDR Phenotype on Outcomes?

  • Montero, María Milagro|||0000-0001-5991-6804
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Knobel Freud, Hernando|||0000-0003-3186-6416
  • Molas, Ema
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Siverio Pares, Ana Cristina
  • Prim, Núria|||0000-0002-5283-0917
  • Segura, Concepción
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Grau, Santiago|||0000-0002-8428-1836
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73-5.46), septic shock (HR 1.75, 95% CI, 1.12-2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12-1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24-0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33-0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance, Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, Mª Carmen
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, Maria Rocío
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77-6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27-6.44) and Charlson index (aOR 1.11; 95% CI 1.01-1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40-0.93) were less likely to present clinical cure. The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. The online version contains supplementary material available at 10.1007/s40121-021-00537-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rates and Predictors of Treatment Failure in Staphylococcus aureus Prosthetic Joint Infections According to Different Management Strategies, A Multinational Cohort Study-The ARTHR-IS Study Group

  • Espíndola, Reinaldo
  • Vella, Venanzio
  • Benito, Natividad|||0000-0001-6410-013X
  • Mur, Isabel|||0000-0001-7660-8483
  • Tedeschi, Sara|||0000-0001-9546-2811
  • Zamparini, Eleonora
  • Hendriks, Johannes G. E.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Murillo Rubio, Oscar|||0000-0001-5776-8422
  • Soldevila-Boixader, Laura|||0000-0003-0649-3785
  • Scarborough, Mathew|||0000-0002-0455-0785
  • Scarborough, Claire
  • Kluytmans, Jan|||0000-0003-2665-6844
  • Ferrari, Mateo Carlo
  • Pletz, Mathias|||0000-0001-8157-2753
  • Mcnamara, Iain
  • Escudero Sánchez, Rosa|||0000-0001-5736-8111
  • Arvieux, Cedric
  • Batailler, Cécile
  • Dauchy, Frédéric Antoine
  • Liu, Wai-Yan
  • Lora-Tamayo, Jaime
  • Praena, Julia
  • Ustianowski, Andrew
  • Cinconze, Elisa
  • Pellegrini, Michele|||0000-0001-8505-9260
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • del Toro López, María Dolores|||0000-0002-4935-8754
Guidelines have improved the management of prosthetic joint infections (PJI). However, it is necessary to reassess the incidence and risk factors for treatment failure (TF) of Staphylococcus aureus PJI (SA-PJI) including functional loss, which has so far been neglected as an outcome. A retrospective cohort study of SA-PJI was performed in 19 European hospitals between 2014 and 2016. The outcome variable was TF, including related mortality, clinical failure and functional loss both after the initial surgical procedure and after all procedures at 18 months. Predictors of TF were identified by logistic regression. Landmark analysis was used to avoid immortal time bias with rifampicin when debridement, antibiotics and implant retention (DAIR) was performed. One hundred twenty cases of SA-PJI were included. TF rates after the first and all surgical procedures performed were 32.8% and 24.2%, respectively. After all procedures, functional loss was 6.0% for DAIR and 17.2% for prosthesis removal. Variables independently associated with TF for the first procedure were Charlson ≥ 2, haemoglobin < 10 g/dL, bacteraemia, polymicrobial infection and additional debridement(s). For DAIR, TF was also associated with a body mass index (BMI).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections, A Randomized Clinical Trial

  • Sojo-Dorado, Jesús
  • López-Hernández, I.
  • Rosso-Fernandez, C.
  • Palacios-Baena, Z.R.
  • Hernández-Torres, A.
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Bereciartua, Elena|||0000-0002-8603-779X
  • García-Vázquez, E.
  • Pintado, Vicente
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Natera-Kindelán, C.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Borrell, Nuria
  • Giner-Oncina, L.
  • Amador-Prous, C.
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Molina, J.
  • Martínez-Alvarez, R.M.
  • Dueñas, C.J.
  • Calvo-Montes, J.
  • Silva, J.T.
  • Cárdenes, M.A.
  • Lecuona, M.
  • Pomar, Virginia|||0000-0002-8473-5834
  • Valiente De Santis, L.
  • Yagüe-Guirao, G.
  • Lobo-Acosta, M.A.
  • Merino-Bohórquez, V.
  • Pascual, A.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Mirelis, Beatriz
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Viñado, Belén|||0000-0001-6212-5886
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Pujol, Miquel|||0000-0002-6475-6208
The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. Design, Setting, and Participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days. Main Outcomes and Measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P =.10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P =.19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P =.006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P =.01). This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections. ClinicalTrials.gov Identifier: NCT02142751.